U.S., April 15 -- ClinicalTrials.gov registry received information related to the study (NCT07529262) titled 'Can Aspirin Reduce the Risk of HCC in Cirrhosis: The AspiRe HCC Trial' on March 19.
Brief Summary: This clinical trial is testing whether taking a low dose aspirin tablet (100 mg) once a day can help prevent liver cancer (hepatocellular carcinoma, HCC) in people who have cirrhosis, which is severe scarring of the liver. People with cirrhosis have a higher risk of developing HCC. Currently, there is no approved treatment that prevents liver cancer in this group.
Research from around the world suggests that low dose aspirin might reduce the risk of liver cancer by up to half and is safe for people with cirrhosis. However, it is not ...